b5media.com

Advertise with us

Enjoying this blog? Check out the rest of the Health & Wellness Channel Subscribe to this Feed

Cancer Commentary, Cancer Treatments, Cancer News, Cancer Stories, Cancer Research.

July 5th, 2007

Tarceva® (erlotinib)-induced Rashes is Better Outcome for Pancreatic and Lung Cancer Patients

OSI Pharmaceuticals, Inc.’s Tarceva® (erlotinib) is indicated for the treatment of pancreatic cancer (first line) and non-small cell lung cancer (second line).
Tarceva (150 mg) is a pill you take once a day — every day — to help treat non-small cell lung cancer.
Tarceva (100 mg) is a pill you take once a day — every […]

By Gloria Gamat -- 0 comments

June 3rd, 2007

ALIMTA® (pemetrexed for injection) and Non-Small Cell Lung Cancer

Manufactured and marketed by Eli Lilly and Company, ALIMTA® (pemetrexed for injection) is indicated as a second-line treatment for non-small cell lung cancer (NSCLC) and in combination with cisplatin is indicated for the treatment of patients with malignant pleural unresectable mesothelioma.
Now, according to Phase III study clinical data, a first-line ALIMTA®-based regimen may deliver less […]

By Gloria Gamat -- 0 comments

March 27th, 2007

Chemo+Radiation is Better than Chemo+Surgery in Some Lung Cancer Patients

In patients with stage IIIA non-small-cell lung cancer, radiation may be a better option than surgery after an initial chemotherapy treatment – according to a randomized controlled trial conducted by Jan van Meerbeeck, M.D., Ph.D., of the University Hospital of Ghent in Belgium, and colleagues from the European Organization for Research and Treatment of Cancer […]

By Gloria Gamat -- 0 comments

January 6th, 2007

Now Open for Patient Enrollment: Stimuvax® Phase III Clinical Trial in Non-small Cell Lung Cancer (NSCLC) Patients

As recently announced by Biomira Inc., the global Phase III clinical trial – START (Stimulating Targeted Antigenic Responses To NSCLC), that is assessing the efficacy and safety of Stimuvax® (BLP25 liposome vaccine) as a potential treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC) is open for patient enrollment.
There are currently no […]

By Gloria Gamat -- 0 comments

October 15th, 2006

Lung Cancer Alliance Hailed USFDA on Approval of Avastin (bevacizumab) for NSCLC

The Lung Cancer Alliance (LCA) has applauded the USFDA on its recent approval of Avastin (bevacizumab) for the most common type of lung cancer.
Laurie Fenton, President of Lung Cancer Alliance in Washington, D.C. stated:
“Lung cancer is responsible for over one-third of all U.S. cancer deaths, killing more people than breast, prostate, colon, liver and kidney […]

By Gloria Gamat -- 0 comments

September 1st, 2006

3D-Radiation Therapy Improves Survival in Early Stage Non-Small Cell Lung Cancer

According to a new study appearing in the September 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the modern three-dimensional radiation therapy proved to be more successful in curing lung cancer as compared to the older two-dimensional radiation therapy in some patients with early stage lung cancer.
87% of all lung cancer diagnosed is non-small […]

By Gloria Gamat -- 0 comments